Neuropace, Inc. NPCE Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value at other companies

ClearPoint NeuroCLPT

——

ITG

Integer HoldingsITGR

——

Relmada Therapeutics, Inc.RLMD

——

BiohavenBHVN

——

Other financials

Income statement

See full

Revenue$22.1M-2.0%

Gross profit$18.0M+4.1%

Operating income-$5.6M-8.2%

Net income-$6.7M-1.5%

EPS (diluted)-$0.20+4.8%

Balance sheet

See full

Cash & equivalents$15.6M-42.4%

Total debt$70.5M-3.7%

Total equity$14.5M-40.4%

Total assets$98.9M-10.3%

Cash flow

See full

Operating cash flow-$5.9M+21.1%

CapEx$117.0K+216%

Free cash flow-$6.0M+20.0%

Valuation

See full

Market cap$557.77M+63.4%

Enterprise value$612.6M+58.1%

P/S5.6×+1.6×

Profitability

See full

Gross margin78.3%+3.5pp

Operating margin-16.8%-3.5pp

Net margin-21.7%-4.5pp

FCF margin-10.3%-3.5pp

Returns & leverage

See full

Return on equity-111.4%-13.1pp

Debt / equity4.9×+1.9×

Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neuropace, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?: Neuropace, Inc. (NPCE) reported share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value of $14.55M in Q1 2026.